The length of follow-up, nearly 10 years in the current study, is also longer than that of similar extension studies of benralizumab 30 mg (administered monthly or every 2 months; BORA extension and MELTEMI OLE), another asthma biologic targeting the IL-5 pathway; in this analysis, the longest follow-up among adult patients was 5 years (total exposure 1581.3 PYs) [37]. The gene discussed is IL5; the disease is asthma.